GTH vs. OM, NGM, FTLF, OMGA, CRDL, KPTI, KNTE, NOTV, BHG, and VTGN
Should you be buying Genetron stock or one of its competitors? The main competitors of Genetron include Outset Medical (OM), NGM Biopharmaceuticals (NGM), FitLife Brands (FTLF), Omega Therapeutics (OMGA), Cardiol Therapeutics (CRDL), Karyopharm Therapeutics (KPTI), Kinnate Biopharma (KNTE), Inotiv (NOTV), Bright Health Group (BHG), and Vistagen Therapeutics (VTGN). These companies are all part of the "medical" sector.
Genetron (NASDAQ:GTH) and Outset Medical (NASDAQ:OM) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, media sentiment, profitability, analyst recommendations, risk, valuation, dividends and community ranking.
In the previous week, Outset Medical had 1 more articles in the media than Genetron. MarketBeat recorded 2 mentions for Outset Medical and 1 mentions for Genetron. Outset Medical's average media sentiment score of 0.33 beat Genetron's score of 0.00 indicating that Outset Medical is being referred to more favorably in the news media.
Outset Medical received 20 more outperform votes than Genetron when rated by MarketBeat users. Likewise, 37.93% of users gave Outset Medical an outperform vote while only 33.33% of users gave Genetron an outperform vote.
Genetron has higher earnings, but lower revenue than Outset Medical.
Genetron has a beta of 0.51, indicating that its share price is 49% less volatile than the S&P 500. Comparatively, Outset Medical has a beta of 1.99, indicating that its share price is 99% more volatile than the S&P 500.
10.7% of Genetron shares are held by institutional investors. 3.5% of Outset Medical shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Genetron has a net margin of 0.00% compared to Outset Medical's net margin of -132.54%. Genetron's return on equity of 0.00% beat Outset Medical's return on equity.
Outset Medical has a consensus price target of $5.42, indicating a potential upside of 112.42%. Given Outset Medical's higher possible upside, analysts clearly believe Outset Medical is more favorable than Genetron.
Summary
Outset Medical beats Genetron on 9 of the 15 factors compared between the two stocks.
Get Genetron News Delivered to You Automatically
Sign up to receive the latest news and ratings for GTH and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GTH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Genetron Competitors List
Related Companies and Tools
